Oct 2, 2015 · Brexpiprazole is approved in the United States for the treatment of schizophrenia, and as an add-on therapy for depression. It was the first treatment approved for agitation associated with …

Curiously, the benefit of brexpiprazole over placebo paled in comparison to the effect of merely participating in the trial, as agitation eased substantially in both the treatment and placebo groups. …

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am J Geriatr Psychiatry. 2020 Apr;28 …

Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2024 Oct;45 (10):4679-4686.

A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease. Expert Rev Neurother. 2025 Jan;25 (1):5-13.

Long X, Liu X, Xia W, Liu L, Chen W. Brexpiprazole Prevents the Malignant Progression of Human Colorectal Cancer Cells and Increases Its Sensitivity to EGFR Inhibition.

Ebina T, Iwamoto K, Ikeda M. Brexpiprazole-related tardive dystonia in a young patient with schizophrenia: A case report. Psychiatry Clin Neurosci. 2024 May;78 (5):334-335.

Dec 20, 2022 · Brexpiprazole also appeared to be effective among participants who had displayed frequent aggressive behaviors—either verbal or physical—at baseline. In both trials, participants …

Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J Affect Disord. 2024 Feb 1;346:223-229.

May 12, 2023 · Brexpiprazole is a derivative of aripiprazole, aka Abilify, an atypical antipsychotic. As a group, such drugs have a sketchy track record in treating agitation in AD, and their side effects had …